Company Profile
Agios Pharmaceuticals, Inc. Stock Price, News & Analysis
- Ticker:
- AGIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
31.95 USD (+0.73%)
Close
Last updated: August 6, 2026
1.58B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AGIO closed up 0.73% at $31.95. No new same-company headline was identified in the current news window.
Company overview
Rare Disease Hematology Company
Agios is a commercial-stage biopharmaceutical company focused on rare diseases, with a foundation in hematology. Its current business is anchored by mitapivat, sold as PYRUKYND and AQVESME, while the company expands into additional rare hematology and metabolic disease programs.
Mitapivat Commercial Expansion
Mitapivat generated $44.7 million in worldwide net revenue in the second quarter of 2026. U.S. revenue was driven by the launch of AQVESME in thalassemia, while ex-U.S. revenue reflected European approval and early demand in Gulf Cooperation Council countries. Mitapivat is now approved for adults with thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and the EU.
Sickle Cell Disease Opportunity
Agios is pursuing mitapivat in sickle cell disease through the FDA accelerated approval pathway. The FDA granted Priority Review for the supplemental NDA, with a PDUFA date of November 1, 2026, and the company has started the REIGNITE confirmatory Phase 3 trial.
Pipeline Diversification
The company is broadening beyond mitapivat. It licensed cevidoplenib, an oral SYK inhibitor for immune thrombocytopenia, and plans Phase 3 development after CMC work. AG-236, an siRNA targeting TMPRSS6, is advancing into Phase 2/3 development for polycythemia vera, while AG-181 is in Phase 1b testing for PKU.
Future catalysts
FDA PDUFA date for mitapivat in sickle cell disease on November 1, 2026.
Phase 2 portion initiation for AG-236 in polycythemia vera in the second half of 2026.
AG-181 Phase 1b data in PKU expected in the second half of 2026.
Cevidoplenib Phase 3 development in ITP expected to begin in the first half of 2028.
Recent news
- 01
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Source: Agios Pharmaceuticals, Inc.
- 02
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Source: Agios Pharmaceuticals, Inc.
- 03
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
Source: Agios Pharmaceuticals, Inc.
- 04
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
Source: Agios Pharmaceuticals, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Agios Pharmaceuticals, Inc. (AGIO)?
Agios Pharmaceuticals, Inc. (AGIO) most recently closed at 31.95 USD, a +0.73% move versus the previous session.
What is the market cap of Agios Pharmaceuticals, Inc. (AGIO)?
Agios Pharmaceuticals, Inc. currently has a market capitalization of 1.58B USD on BioPharmSignal.
What does Agios Pharmaceuticals, Inc. do?
Rare Disease Hematology Company Agios is a commercial-stage biopharmaceutical company focused on rare diseases, with a foundation in hematology. Its current business is anchored by mitapivat, sold as PYRUKYND and AQVESME, while the company expands into additional rare hematology and metabolic disease programs. Mitapivat Commercial Expansion Mitapivat...
On which exchange is AGIO stock listed?
Agios Pharmaceuticals, Inc. (AGIO) is associated with NASDAQ, United States, Biopharma.
What is AG-236?
Phase 2 portion initiation for AG-236 in polycythemia vera in the second half of 2026.
Which conditions is Agios Pharmaceuticals, Inc. targeting with AG-236?
Agios Pharmaceuticals, Inc. is associated with rare disease, metabolic disease, hematology based on its company overview and current catalyst commentary.
How does Agios Pharmaceuticals, Inc. describe recent progress with AG-236?
Phase 2 portion initiation for AG-236 in polycythemia vera in the second half of 2026.
What is AG-181?
AG-236, an siRNA targeting TMPRSS6, is advancing into Phase 2/3 development for polycythemia vera, while AG-181 is in Phase 1b testing for PKU.